Optimizing a Pre-Clinical Mouse Model for Cancer Chemotherapy: Thirty-two Fold Increase in Maximum Tolerated Dose for a Novel Amidoxime with Anti-Cancer Properties

Date
2021
Authors
Underbrink, Karen
Ngo, Thao
Ladell, Tahree
Sor, Jessica
Rodriguez, Cecily
Nimely, Erica
Meza, Elizabeth
Martinez, Marcus
Magoha, Crystal
Thayer, Veronica
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract

Chemotherapy treatment often follows tumor removal, with goals of preventing regrowth or metastasis from remaining cancerous cells. Our laboratory uses a mouse model for breast cancer chemotherapy, treating with novel compounds developed by Drs. Johnson and Bergel. We have demonstrated that the recently patented amidoxime JJMB9 affected mouse mammary tumor volume and metastasis. These results used a maximum tolerated dose (MTD) of JJMB9 established with a sesame oil-DMSO vehicle. Several mice receiving vehicle only died during those experiments, while an oil-free vehicle used in the last experiment resulted in no deaths. Accordingly, we have performed experiments to re-establish a maximum tolerated dose (90% survival) by progressively doubling the original 0.78 mg/kg dose. Each concentration increase resulted in zero deaths, establishing MTD of 25 mg/kg, thirty-two times the previous MTD. A further increase to 50 mg/kg compromised the mice’s health. These results allow more effective chemotherapy in our mouse model system.

Description
Creative Arts and Research Symposium
Creative Arts and Research Symposium
Keywords
Citation